Bristol-Myers to collaborate on immuno-oncology studies

Bristol-Myers Squibb ($BMY) has signed on Northwestern University to partner on some early-stage immunotherapy trials. Bristol-Myers, one of the leaders in the immuno-oncology field, will collaborate with Lurie Cancer Center and NMDTI on new studies related to small, genetically defined patient subpopulations. "Complementing our broad research and development programs through innovative collaborations with partners such as the Lurie Cancer Center and NMDTI has been a fundamental component to our commitment to leading advances in Immuno-Oncology," said Dr. Laura Bessen, head of U.S. Medical, Bristol-Myers Squibb. Release

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.